Cyp2d Knockout Mouse

Constitutive Knock Out

Cyp2d Constitutive Knock Out Mouse Model

  • Model #
  • Genotype
  • Nomenclature
  • 9178-F
    ko/ko
    C57BL/6-Del(15Cyp2d22-Cyp2d26)1Arte
  • 9178-M
    ko/ko
    C57BL/6-Del(15Cyp2d22-Cyp2d26)1Arte
  • This model carries disruptions or deletions of all nine full-length mouse Cyp2d genes identified.
  • Contains a Cre-mediated deletion of the following genes in the Cyp2d cluster: Cyp2d22, Cyp2d11, Cyp2d10, Cyp2d9, Cyp2d12, Cyp2d34, Cyp2d13, Cyp2d40 and Cyp2d26.
  • In humans, CYP2D6 metabolizes approximately 25% of all marketed drugs.
  • Useful in dissecting the contribution of the Cyp2d family to total bioavailability of a drug.
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.

Origin:

The Cyp2d Knockout Mouse was developed by Taconic in collaboration with CXR Biosciences. It was generated by crossing a CYP2D6 humanized mouse line with a Flpe deleter mouse. The Humanized CYP2D6 Mouse model was created by first replacing mouse exon 1 to 4 of Cyp2d26 with a hygromycin cassette containing both loxP and frt sites and subsequently replacing mouse exons 4 and 5 of Cyp2d22 with a human CYP2D6 expression cassette containing additional loxP and frt sites through gene targeting in C57BL/6NTac-derived ES cells. The targeted ES cells were injected into BALB/cJBomTac blastocysts and the resultant chimeras were backcrossed to a Cre deleter strain on C57BL/6J to delete the mouse Cyp2d26 cluster. The Cyp2d Knockout Mouse model was derived from the Humanized CYP2D6 Mouse line through a Flpe-mediated deletion of the human CYP2D6 sequence. The absence of functional Cyp2d proteins was proven experimentally. Taconic received stock in 2009, and the line was embryo transfer derived. The colony is maintained by mating homozygotes.

Color:

Black

Species:

Mouse

Initial Publication:

Scheer N, Kapelyukh Y, Ross J, Beuger V, Stanley LA, Rode A, Wolf CR (2011) Modeling human cytochrome P450 2D6 metabolism and drug-drug interaction by a novel panel of knockout and humanized mouse lines. Mol Pharmacol, October 11, 2011 mol.111.075192, published ahead of print.


Conditions of Use for Emerging Models
Emerging Models are produced and distributed under rights to patents and intellectual property licensed from various institutions. Taconic sells the Models to purchasers, grants to each purchaser a right under Taconic's rights in such licensed patents and intellectual property to use the purchased Model in consideration of purchasers' acknowledgement of and agreement to the Terms and Conditions of Sale and the following terms of use:
  • Title to these Models and biological materials derived from them remains with Taconic Biosciences, Inc.
  • The Models will be used for research purposes only.
  • The Models will not be bred or cross-bred except to obtain embryos or fetuses required for research purposes unless a breeding or cross-breeding agreement has been legally executed. Please contact Taconic Customer Service for details.
  • The Models and biological materials derived from them will not be distributed to third parties or used for commercial purposes.
  • Non-profit purchasers may not use this Model and/or biological materials derived from it in sponsored research or contract research studies unless it is purchased at the for-profit price.
Conditions of Use - Printable Version